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ABSTRACT
Introduction: Pseudomonas aeruginosa is a gram-negative, opportunistic pathogen causing 
infections in patients staying in the hospital and is resistant to multiple drugs. This study 
investigated the resistance to ciprofloxacin by the efflux system of Pseudomonas aeruginosa. 
Materials and Methods: For this purpose, the inhibitor of the efflux system phenylalanine-
arginine beta-naphthylamide was used. In this study, 135 isolates of Pseudomonas aeruginosa 
were collected from the hospitalized patients of Imam Khomeini Hospital and outpatient clinics 
in Urmia during a ten-month period from June 2015 to March 2016. These isolates were re-
identified by standard microbiological and biochemical methods. Finally, 51 isolates were 
selected for antibiotic susceptibility testing. Results: According to the antibiogram test, the 
Pseudomonas aeruginosa isolates exhibited highest resistance against ciprofloxacin (90.2%), 
tobramycin (88.2%), and gentamycin (86.3%) and the highest sensitivity towards colistin 
(76.4%), and imipenem (72.5%). The 51 isolates, which were selected for the minimum 
inhibitory concentration test, had multi-drug resistance regulators. Conclusion: The discovery 
and development of the efflux system inhibitors is an important strategy to deal with bacterial 
infections.
INTRODUCTION
Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative 
opportunistic pathogen causing infection in patients with a 
compromised host defense system such as burn injuries, 
acute keratitis, and cystic fibrosis (1). The treatment of in-
fections in hospitalized patients is difficult due to the pres-
ence of antibiotic-resistant isolates (2). P. aeruginosa is the 
leading cause of death among people with cystic fibrosis (3). 
P. aeruginosa has several virulence factors, such as pili, fla-
gella and mucoid glycocalyx that contributes to the muco-
sal environment of the bacteria and also helps the bacteria 
against phagocytosis and immunization (1). In addition, it 
has secretory factors, such as proteases and enzymes, the ex-
pression of which is controlled by quorum sensing (4). High 
levels of intrinsic and acquired resistance to a wide range of 
antimicrobial agents, including most β-lactams, fluoroquino-
lones, macrolides, aminoglycosides, tetracycline, chloram-
phenicol and other antimicrobial agents are observed that is 
clinically important (5). The intrinsic resistance is the result 
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of the high expression of the efflux pumps, the production 
of high AmpC chromosomes and the loss of purines, while 
the acquired resistance is due to the acquisition of resistance 
genes, such as an extended spectrum of β-lactams (blaSHV, 
blaTEM, blaVEB, blaPER, blaOXA), and carbapenemases 
(blaGES, blaKPC, blaIMP, blaSPM, blaVIM, blaNDM) (6). 
The resistance is due to a combination of the following fac-
tors; intrinsic resistance to antimicrobial agents due to the 
cell wall penetrability, genetic capacity to express a broad set 
of resistance mechanisms, mutations in chromosomal genes 
that regulates the expression of resistance genes, and acqui-
sition of resistance genes from other organisms through plas-
mids, transposons, and bacteriophages (7). The resistance 
due to efflux system is a growing global problem now (8).
As a result of the activity of the efflux pumps, the con-
centration of many antibiotics in the bacterial cell decreases; 
thus resulting in structural resistance to many unconnect-
ed antibiotic classes (9). Another reason for the intrinsic 
resistance of P. aeruginosa to some antibiotics is the low 
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permeability of the outer membrane (one hundredth of the 
outer membrane of Escherichia coli (E. coli)) (10). Indeed, 
the intrinsic multi-drug resistance of this organism is due to 
the synergism of efflux pumps and a low permeability of the 
outer membrane (11). Biofilm formation protects this bac-
terium from host immune responses, and results in survival 
and increased resistance to antimicrobial agents (12). Ex-
pression of the efflux pumps is one of the reasons for the 
resistance of biofilm bacteria to various antimicrobial agents 
(13). Recently, Zhang et al. reported a new efflux pump 
PA1877-1818 in P. aeruginosa, whose expression was high-
er in biofilms compared to planktonic growth and appears 
to be involved in the antibiotic resistance of biofilms (14). 
The main efflux system involved in multiple-drug resistance 
in P. aeruginosa belong the resistance-nodulation-division 
(RND) family, which pull out a wide range of drugs and 
other substrates to the outside of the cell. Among the RND 
efflux systems, four efflux pumps MexAB-OprM, Mex-
CD-OprJ, MexEF-OprN, and MexXY-OprM have the high-
est clinical significance in P. aeruginosa, which are different 
in terms of their expression pattern and substrate specificity 
(15). Therefore, using inhibitors of the efflux system can re-
duce the activity of these pumps and increase the activity of 
various pharmaceutical agents (substrates of these pumps) 
against pathogenic bacteria (16).
In this study, phenylalanine-arginine beta-naphthylam-
ide (PAβN) was used as an inhibitor of the efflux system to 
evaluate its effect on the minimum inhibitory concentration 
of ciprofloxacin antibiotic as a pump substrate and its effect 
on P. aeruginosa resistance against ciprofloxacin was inves-
tigated.
MATERIALS AND METHODS
Data collection and P. aeruginosa isolates; A number of 
P. aeruginosa isolates from different clinical specimens, 
including urine, wound secretions, tracheotomy, blood 
samples, and bronchus of patients referred to the Imam Kho-
meini Hospital of Urmia were collected from June 2015 to 
March 2016 and transferred to the medicine faculty. The col-
lected samples were cultured on the Muller Hinton agar, and 
suspected colonies were purified and re-identified. Identifica-
tion of the isolates was carried out through standard microbi-
ology methods, including hot staining, colony morphology, 
movement evaluation, indole methyle red voges proskauer 
and citrate (IMViC) test and specific biochemical test, such 
as oxidase test. Finally, 51 isolates of P. aeruginosa were 
selected for the antibiotic susceptibility test.
Antibiotic susceptibility test and determination of min-
imum inhibitory concentration (MIC) of ciprofloxacin; An 
antibiotic susceptibility test for P. aeruginosa isolates was 
performed on Muller Hinton agar based on Clinical & Lab-
oratory Standards Institute (CLSI) (17) using diffusion disk 
(Kirby-Bauer) method. The antibiotic disks (MAST, made by 
U.K.) were imipenem (10 μg), aztreonam (10 μg), cefepime 
(30 μg), ceftazidime (30 μg), gentamicin (10 μg), ciproflox-
acin (30 μg), tobramycin (10 μg), colistin (10 μg), amikacin 
(30 μg), piperacillin-tazobactam (10/100 μg). In this meth-
od, bacterial suspensions were prepared as 0.5 McFarland 
and spread on the Muller Hinton agar. Then, antibiotic disks 
were placed at appropriate intervals on the agar and incu-
bated at 35°C for 16 h. After this time, the diameter of the 
halo around each disc was measured and the results were re-
corded. Positive control and negative control strains for the 
antibiogram included P. aeruginosa ATCC 27853 and E. coli 
ATCC 25922, respectively. In the next step, the minimum in-
hibitory concentration (MIC) of ciprofloxacin against these 
isolates was determined by the broth microdilution method. 
Serial dilutions (0.225-125 μg/ml) of the antibiotic were pre-
pared for the MIC test.
The antibiotic ciprofloxacin was purchased in the form 
of a lyophilized powder (SIGMA ALDRICH) and was dis-
solved in its appropriate solvent (sterile water) and an an-
tibiotic stock (ten times more concentration) was prepared 
((ESCMID) -2003- Clinical_Microbiology_and_Infection). 
The MIC test was carried out in 96-well microplates, each 
row had a specific isolate, along with a positive control well 
(a mixture of a Muller Hinton broth and bacterial suspen-
sion) and a negative control well (a mixture of Muller Hinton 
broth and antibiotics), and incubated for 18 h at 35°C and the 
results were recorded and analyzed according to the stan-
dards set by CLSI.
Determination of MIC of ciprofloxacin in presence of 
PAβN: As already known, efflux systems are one of the main 
reasons for the resistance to antibiotics (18). To demonstrate 
the role of these systems of P. aeruginosa in ciprofloxacin 
resistance, the MIC test for the isolates of ciprofloxacin-re-
sistant bacteria were performed in the presence of the PAβN 
inhibitor. The purified isolates of P. aeruginosa were ex-
posed to 50 μg/ml of PAβN (15, 19) and then cultured on 
the Muller Hinton Agar and incubated for 24 h at 35°C. The 
MIC tests were performed using serial dilutions of ciproflox-
acin (0.125-0.256 μg/ml). The result was recorded according 
to CLSI.
RESULTS
Out of the 135 isolates, 51 were selected for antibiotic 
susceptibility testing. Antibiogram test showed highest re-
sistance of the P. aeruginosa isolates against ciprofloxacin 
(90.2%), tobramycin (88.2%), gentamycin (86.3%), and the 
highest sensitivity against colistin (76.4%) and imipenem 
(72.5%). All the 51 isolates had multidrug resistance regula-
tors (MDRs) (Table 1).
The MIC results were compared with the standards set 
by CLSI. Based on the comparison, 45 isolates (88.2%) 
showed resistance and 2 isolates (3.9%) exhibited inter-
mediate resistance to ciprofloxacin. Four isolates (7.8%) 
showed sensitivity to ciprofloxacin. To evaluate the effect 
of efflux inhibitor PAβN on the minimum inhibitory con-
centration of this antibiotic, antibiotic susceptibility test in 
the presence of this efflux inhibitor was performed with 
47 isolates that were resistant to ciprofloxacin. The results 
were classified as sensitive, intermediate and resistant. In 
the presence of the efflux inhibitor, the resistance to cipro-
floxacin decreased by 12.8%. The results of are presented 
in Table 2.
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DISCUSSION
For many years, Pseudomonas aeruginosa has been recog-
nized as the leading cause of ulcer and surgical infections. 
It is an opportunistic and invasive secondary pathogenic 
bacterium that does not cause infection in healthy tissues. 
It is mainly found in patients with immunodeficiency and 
in patients with cystic fibrosis (20). This organism shows 
a high level of intrinsic resistance and only a limited num-
ber of antimicrobial agents are active against it. In addition, 
P. aeruginosa is able to withstand the existing anti-Pseudo-
monas agents (21).
Efflux pumps are one of the important causes of multiple 
drug resistance in bacteria (22). However, the high preva-
lence of resistance in bacteria is not due to the presence of 
the multi-drug efflux system; nevertheless, the expression 
of efflux system genes cannot be ignored in the MDR iso-
lates (23). Since, inhibition of the efflux system can increase 
the intracellular concentration of drugs and thus increase 
their effectiveness, the discovery and development of the ef-
flux system inhibitors is an important strategy to deal with 
bacterial infections (15).
In this study, when the MIC test was performed with 
the 51 isolates using the microdilution method, 45 isolates 
(88.23%) were resistant and 2 isolates (3.92%) showed an 
intermediate resistance to ciprofloxacin. The results of this 
study were consistent with the study of Adabi et al. (21), 
where sensitivity test using dilution agar method showed re-
sistance to this antibiotic in 127 isolates (82.5%), although 
the volume of the isolates in the two studies were different. 
However, the resistance rate for ciprofloxacin was higher 
in our study compared to the study of Sonnet et al., where, 
approximately 25% of the isolates were resistant (19). Gilli 
et al., during two years (2014-2015) in India, determined the 
susceptibility pattern of P. aeruginosa isolates by the MIC 
method using the Vitek2 system and showed that 96% of 
the isolates were resistant to ciprofloxacin and 44% of the 
studied isolates had MDR phenotype (22).
In the presence of PAβN, the efflux system inhibitor, 
61.7% of the isolates showed 2-2.56 times reduction in MIC 
of ciprofloxacin, of which 44.7% exhibited two times reduc-
tion of the MIC. This result was consistent with the study 
carried out by Fernando and Kumar, who reported that fluo-
roquinolones are the major substrates for the efflux pumps in 
P. aeruginosa isolates (24).
On the other hand, 38.8% of the isolates did not show any 
reduction in the MIC levels of ciprofloxacin in the presence 
of inhibitors. Mechanisms, such as mutations in the target 
enzyme (DNA gyrase) were likely to be involved in the re-
sistance of these isolates against ciprofloxacin (20).
Walkty et al. examined the drug resistance pattern of 
2906 clinical isolates of P. aeruginosa by microdilution 
method and found that 23.5% of the isolates exhibited re-
sistance or intermediate resistance. In 421 isolates with 
MDR phenotype, the resistance to ciprofloxacin was 77% in 
this study (23). In a similar study, Sader et al. reported that 
66.5% of the MDR isolates of P. aeruginosa were resistant 
to ciprofloxacin (24).
Other studies have also shown a 23% to 57% resistance 
of the P. aeruginosa isolates against ciprofloxacin (25-27). 
Negi et al. reported that 18% of the P. aeruginosa isolates 
were resistant to more than 3 classes of antibiotics (27).
Many studies have been conducted on the resistance pat-
terns of P. aeruginosa in Iran and other countries, and the 
results are different. The results are dependent on the type of 
sample and the differences in the origin of the isolates, time 
and place, the method and technique of studying and the use 
of antibiotics. P. aeruginosa has become resistant to more 
number of antibiotics in the recent years (28- 30), and this 
resistance is increasing rapidly.
Pseudomonas aeruginosa is resistant to all the existing 
anti-Pseudomonas agents (21). The efflux system, or the 
active transfer of antibiotics outside the cell, is also a ma-
jor cause of multiple drug resistance in bacteria, including 
P. aeruginosa (31). However, the high prevalence of resis-
tance in bacteria is not due to the presence of a multi-drug 
efflux system alone. The expression of the efflux system in 
the MDR isolates cannot be ignored (32). Since inhibition 
of the efflux system can increase the intracellular concentra-
tion of drugs and increase their effectiveness, the discovery 
and development of the inhibitors of the efflux system is an 
important strategy for coping with bacterial infections (15).
In the presence of an inhibitor, 47 isolates were found to be 
resistant to ciprofloxacin, 29 isolates showed a 2 fold or more 
reduction in MIC, while in a previous study by Sonnet et al., 
27 isolates were resistant to ciprofloxacin, and 25 isolates 
Table 1. Antibiotic susceptibility pattern of P. aeruginosa 
isolates using disk diffusion method
Susceptible 
N (%) 
Intermediate 
N (%) 
Resistant 
N (%) 
Antibiotic
37 (72.5%)4 (7.8%)10 (19.6%)Imipenem
15 (29.4%)5 (9.8%)31 (60.8%)Ceftazidime
7 (13.7%)12 (23.5%)32 (62.7%)Aztreonam
13 (25.5%)4 (7.8%)34 (66.7%)Cefepime
39 (76.5%)-12 (23.5%)Colistin
2 (3.9%)3 (5.9%)46 (90.2%)Ciprofloxacin
29 (56.9%)2 (3.9%)20 (39.2%)Amikacin
6 (11.7%)1 (2%)44 (86.3%)Gentamicin
5 (9.8%)1 (2%)45 (88.2%)Tobramycin
14 (27.5%)18 (35.3%)19 (37.2%)Piperacillin/
Tazobactam
Table 2. Minimum inhibitory concentration of ciprofloxacin for MDR isolates of P. aeruginosa
Antibiotic In the absence of inhibitor In the presence of inhibitor
Resistant N (%) Susceptible N (%) Resistant N (%) 
Ciprofloxacin 47 (100) 6 (12.8) 41 (87.2)
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showed a 4 fold or more reduction in MIC (19). The com-
parison of these two studies suggests that MIC reduction in 
the presence of inhibitor in our study was twice as low as in 
the study of Sonnet et al. One of the most probable reasons is 
that in our isolates, mechanisms other than the activity of the 
efflux system have been implicated in resistance to ciprofloxa-
cin, and therefore, the inhibitor of the above-mentioned efflux 
system has little effect on the reduction of MIC. Lomovskaya 
et al. believed that the use of an inhibitor of the early efflux 
system could prevent resistance to fluoroquinolones (33).
CONCLUSION
The discovery and development of the efflux system inhibi-
tors is an important strategy to deal with bacterial infections 
and the inhibition of the efflux system has little effect on the 
reduction of MIC.
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